Parabilis Medicines CMO to Depart Effective Sept 30, 2026

What Happened
Parabilis Medicines, Inc. filed a Form 8-K (Item 5.02) on September 2, 2026, reporting that Chief Medical Officer Dr. Fawzi Benzaghou and the company mutually agreed he will transition from his role effective September 30, 2026. The company said Dr. Benzaghou will receive severance benefits as specified in his employment agreement.

Key Details

• Filing: Form 8-K filed September 2, 2026 (Item 5.02).
• Officer: Dr. Fawzi Benzaghou, Chief Medical Officer.
• Effective date: Transition effective September 30, 2026.
• Severance: Dr. Benzaghou will receive severance per his employment agreement; no dollar amount disclosed.

Why It Matters
This is an executive leadership change that could affect Parabilis’s clinical and development oversight given the CMO’s role in medical strategy and clinical programs. The company disclosed that departure is by mutual agreement and that severance will follow the existing contract, but provided no financial details. Investors should note the change and watch for any subsequent announcements about an interim or replacement CMO and potential impacts on clinical timelines or disclosures.